Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, n

[News]

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

More... (http://www.news-medical.net/?id=37552)